Female Viagra
In brief
- In our pharmacy you can buy “female viagra” without a prescription, with delivery across Australia and discreet packaging; note that licensed products (flibanserin/Addyi and bremelanotide/Vyleesi) are prescription-only in regulated markets, while many over‑the‑counter “female Viagra” products sold without a script are sildenafil‑based generics.
- “Female Viagra” refers to several products used to address low sexual desire or sexual arousal problems in women: flibanserin (for acquired, generalized hypoactive sexual desire disorder in premenopausal women) acts on central neurotransmitters (5‑HT1A agonist / 5‑HT2A antagonist, modulating dopamine, norepinephrine and serotonin); bremelanotide is a melanocortin receptor agonist given before sex; many OTC products labelled as “female Viagra” contain sildenafil, a PDE5 inhibitor that increases genital blood flow (not approved for HSDD by major regulators).
- Usual dosages: flibanserin 100 mg orally once nightly; bremelanotide 1.75 mg subcutaneous injection given ≥45 minutes before sexual activity (maximum 1 dose per 24 hours and 8 doses per month); sildenafil generics typically sold as single 50–100 mg oral doses taken before sex (note: sildenafil is not approved for female HSDD).
- Form of administration: flibanserin — oral film‑coated tablet; bremelanotide — single‑use subcutaneous autoinjector; sildenafil generics — oral tablets.
- Onset time: flibanserin usually requires continuous nightly dosing and may take several weeks to show benefit (reassess around 4–8 weeks); bremelanotide usually begins to work within about 30–60 minutes; sildenafil (where used off‑label) commonly starts within 30–60 minutes.
- Duration of action: flibanserin provides ongoing effect only while taken nightly; bremelanotide’s clinical effect is typically over several hours after injection (varies between individuals); sildenafil’s effect commonly lasts about 4–5 hours.
- Alcohol warning: do not consume alcohol with flibanserin (risk of severe hypotension and syncope); avoid heavy alcohol use with bremelanotide and be cautious with sildenafil—also avoid sildenafil with nitrates or certain interacting medicines.
- The most common side effec is nausea.
- Would you like to try “female viagra” without a prescription?
Basic Female Viagra Information
- INN (International Nonproprietary Name): The term “female Viagra” generally refers to flibanserin and, less commonly, bremelanotide, both approved for hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Brand Names Available In Australia: Addyi (flibanserin) and Vyleesi (bremelanotide) are the principal brand names noted internationally; other sildenafil-based products marketed as “female Viagra” (for example Vibasuva F) exist in some countries such as India but are not approved for HSDD by major regulators.
- ATC Code: Flibanserin — G02CX01. Bremelanotide — G02CX06.
- Forms & Dosages: Flibanserin 100 mg oral tablets for nightly dosing. Bremelanotide 1.75 mg pre-filled single-use subcutaneous autoinjector for use ≥45 minutes before sexual activity, up to 1 dose per 24 hours and 8 doses per month. Sildenafil generics marketed in some regions as “female Viagra” are typically 100 mg oral tablets but are not approved for HSDD.
- Manufacturers In Australia: Not specified in the raw data; internationally listed manufacturers include Sprout Pharmaceuticals for Addyi and AMAG Pharmaceuticals for Vyleesi, with various generic sildenafil manufacturers supplying other markets.
- Registration Status In Australia: Not specified in the raw data; clinicians and pharmacists should check the TGA ARTG for current registration details before prescribing or dispensing.
- OTC / Rx Classification: Addyi and Vyleesi are prescription-only (Rx) in regulated markets. Some sildenafil products marketed as female enhancers are sold OTC in certain countries but are not approved for HSDD by major authorities.
Critical Warnings, Restrictions And Patient Protection (Australia Focus)
High-Risk Groups (Elderly, Pregnancy, Chronic Illness)
Who should not take these medicines is the first safety question people ask.
Absolute contraindications include pregnancy, breastfeeding and known hypersensitivity to the active ingredient.
Flibanserin is contraindicated in severe hepatic impairment and in people who consume alcohol regularly because of a risk of hypotension and syncope.
Use of strong CYP3A4 inhibitors with flibanserin is contraindicated due to increased exposure and risk of adverse effects.
Bremelanotide requires caution in patients with significant hepatic or renal impairment and is not recommended without review in those groups.
People aged over 65 are not recommended to start these medicines because safety and efficacy have not been established in that age group.
Contraindication Checklist:
- [ ] Pregnancy.
- [ ] Breastfeeding.
- [ ] Severe liver disease (flibanserin contraindicated).
- [ ] Concurrent strong CYP3A4 inhibitor use (e.g. ketoconazole).
- [ ] Regular alcohol use (important for flibanserin).
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Patients commonly want to know if the medicine will affect their ability to drive or work safely.
Flibanserin commonly causes dizziness, somnolence and occasional syncope, particularly when combined with alcohol or interacting drugs.
Bremelanotide is more often associated with nausea, flushing and occasional dizziness or vertigo after injection.
Advise patients not to drive, operate heavy machinery or perform safety-critical tasks until they know how the medication affects them.
For safety-critical roles under Australian workplace law, note that impairment from dizziness or sleepiness may compromise fitness for duty and should be discussed with the employer or occupational health adviser.
Document counselling and recommend written advice to take to the employer if a fitness-for-work note is required.
Q&A — Can I Drive After Taking It In Australia?
Short answer: Do not drive if you feel dizzy, sleepy or faint after taking the medicine.
Before driving, confirm you have had no dizziness, somnolence, syncope or severe nausea following the dose.
Immediate actions if affected include sitting or lying down until symptoms resolve and avoiding further alcohol or sedating medicines.
Seek urgent medical help for collapse, loss of consciousness, or prolonged fainting.
Report adverse effects to the TGA via their Adverse Event reporting service.
Pharmacists can assist with immediate counselling and advise contacting the prescribing clinician for a medication review.
Usage Basics — What “Female Viagra” Refers To And Legal Status
INN, Brand Names And What Australians Hear In Media
People often search for “female viagra” when they mean a treatment for low sexual desire.
The INNs commonly associated with this term are flibanserin and bremelanotide.
Brand names internationally include Addyi for flibanserin and Vyleesi for bremelanotide.
Sildenafil-based products are sometimes marketed as “female Viagra” in countries such as India but are not approved for HSDD by major regulators.
Australian media may use the shorthand “female viagra” when discussing Addyi or Vyleesi, so clarify the active ingredient when advising patients.
Short definition list:
- Flibanserin — Addyi — nightly oral tablet for HSDD.
- Bremelanotide — Vyleesi — on-demand subcutaneous injection for HSDD.
- Sildenafil generics — not approved for HSDD; often intended for erectile dysfunction.
Legal Classification (TGA, PBS, Prescription Status)
Both Addyi (flibanserin) and Vyleesi (bremelanotide) are prescription-only medicines in regulated markets.
Patients should be told to check TGA registration status and ARTG entries before assuming availability in Australia.
Neither medicine is likely to be PBS-listed based on international availability, so private prescription cost usually applies.
Regulatory Status Table:
| INN | FDA Status | TGA Status | PBS Listing |
|---|---|---|---|
| Flibanserin (Addyi) | Approved for premenopausal HSDD | Check ARTG (not specified in raw data) | Not specified / likely not listed |
| Bremelanotide (Vyleesi) | Approved for premenopausal HSDD | Check ARTG (not specified in raw data) | Not specified / likely not listed |
- Confirm identity with your pharmacist when collecting the medicine.
- Request the printed medication information leaflet and keep it for reference.
- Check Australian import rules and customs if ordering from overseas online pharmacies.
Dosing Guide And Regimen Practicalities
Standard Regimens And Australian Practice Notes
Flibanserin is prescribed as 100 mg orally at bedtime each night.
It is taken continuously and should be reassessed for benefit and safety after about eight weeks.
Bremelanotide is supplied as a 1.75 mg pre-filled subcutaneous autoinjector for use at least 45 minutes before sexual activity.
Do not exceed one dose within 24 hours or eight doses per month for bremelanotide.
Explain clearly the difference between nightly adherence for flibanserin and as-needed dosing for bremelanotide.
Practical counselling includes demonstration of injection technique for Vyleesi and establishing a routine bedtime dosing time for Addyi.
Adjustments For Comorbidities And Monitoring
Flibanserin is contraindicated in severe hepatic impairment and requires caution in moderate liver disease.
Bremelanotide needs dose caution or avoidance in patients with significant hepatic or renal impairment.
Elderly patients over 65 are not recommended to start either medicine because safety and efficacy are not established.
Review the patient’s medication list for strong CYP3A4 inhibitors before starting flibanserin and consider baseline liver function tests when clinically indicated.
Monitor for dizziness, somnolence, syncope and hypotension with flibanserin and for nausea and blood pressure changes with bremelanotide.
Q&A — What If I Miss A Dose?
Flibanserin (Addyi): If you miss a nightly dose, skip it and take the next dose at the usual time.
Do not double the dose to make up for a missed tablet.
Bremelanotide (Vyleesi): If you miss a pre-sex injection, do not inject at a different time to “catch up”.
For suspected overdose of bremelanotide, seek urgent assessment; monitoring for elevated blood pressure and nausea is advised.
Contact your GP or pharmacist for specific advice if doses are missed repeatedly or if adverse effects occur.
Interaction Chart — Food, Drink And Drug Conflicts
Alcohol, Diet And Common Australian Cultural Factors
The single most important lifestyle interaction is alcohol with flibanserin.
Concurrent alcohol use increases the risk of symptomatic hypotension and syncope with flibanserin.
Given the role of social drinking at events and festivals across Australia, pharmacists should counsel clearly on alcohol avoidance during treatment.
Advise patients to avoid alcohol for at least several hours before and after taking flibanserin and to discuss planned social events with their prescriber.
Provide a short patient script for pharmacists to use that highlights the alcohol-safety message in plain language.
Common Drug Conflicts And CYP Interactions
Strong CYP3A4 inhibitors substantially increase flibanserin exposure and are contraindicated when on flibanserin.
Examples include ketoconazole and certain macrolide antibiotics such as clarithromycin, and some antiretrovirals.
Moderate inhibitors also require caution and prescriber review before starting flibanserin.
Drug Interactions Quick-Check:
| Concomitant Drug | Interaction Type | Action |
|---|---|---|
| Ketoconazole | Strong CYP3A4 inhibitor | Contraindicated with flibanserin |
| Clarithromycin | Strong CYP3A4 inhibitor | Contraindicated with flibanserin |
| Common antiretrovirals | Variable CYP effects | Check specialist guidance before co-administration |
- Ask about herbal remedies such as St John’s wort; it can alter CYP activity.
- Query common OTC medicines and recreational drugs during consultation.
User Reports, Trends And Lived Experience (Australia)
Patients look to online reviews and forums for lived experience but anecdote is not a substitute for clinical data.
Sources in Australia include ProductReview, local health forums, peer support groups and pharmacy consultation notes.
Pharmacists should explain the difference between randomized clinical trial outcomes and individual patient stories.
Report summaries are useful for shared decision-making and should separate benefits from harms clearly.
Suggested summary table for pharmacy use:
| Reported Benefit | Reported Side Effects | Reason For Discontinuation |
|---|---|---|
| Improved desire scores in some patients | Dizziness, somnolence, nausea | Intolerable side effects |
Collecting patient-reported outcomes in clinic is recommended using baseline desire scales and an adverse-event diary.
Access and uptake may differ between urban and rural Australia, with telehealth increasing reach but cost sensitivity remaining important.
Access & Purchase Options In Australia
Community Pharmacy Chains, Private Clinics And Telehealth
Major community pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart can be starting points for enquiries.
Patients should call ahead to check stock and whether the pharmacy will dispense a prescription or provide counselling.
Telehealth consultations with a GP can supply an e-prescription where clinically appropriate.
In our online pharmacy, female viagra is available without a prescription, with discreet delivery to Australia in 9-21 days.
For any private clinic prescribing, confirm the prescriber’s credentials and documentation.
Online Pharmacies, Rural Access And Safeguards
Safe online purchase checklist:
- Confirm the product is TGA-approved or check ARTG if applicable.
- Ensure a valid prescription is in place unless local laws allow otherwise.
- Verify supplier ABN and pharmacy registration details.
- Confirm a real pharmacist is available for counselling.
| Source | Prescription Required | Typical Wait | Counselling Offered | Risk Level |
|---|---|---|---|---|
| Community Pharmacy | Yes | Same day to 2 days | Yes | Low |
| Telehealth / Private Clinic | Yes | Same day to 7 days | Yes | Low–Medium |
| Unregulated Overseas Site | Varies | 7–21 days | No | High |
Mechanism Of Action & Pharmacology (Lay + Clinical)
Simplified Explanation For Patients
Patients ask if these are hormones or “like Viagra for women”.
Flibanserin acts centrally by modulating serotonin and dopamine pathways to help increase sexual desire and is non-hormonal.
It is taken nightly rather than around the time of sex.
Bremelanotide works as a melanocortin receptor agonist and is injected before sexual activity to enhance sexual response in some women.
Individual response varies and not everyone will notice benefit.
Clinical Terms And Deeper Pharmacology For Clinicians
Key definitions for clinicians:
- HSDD — Hypoactive Sexual Desire Disorder, acquired and generalized in premenopausal women as per trial definitions.
- INN — International Nonproprietary Name (flibanserin, bremelanotide).
- ATC codes — Flibanserin G02CX01; Bremelanotide G02CX06.
Comparative pharmacology summary:
| Feature | Flibanserin | Bremelanotide |
|---|---|---|
| Route | Oral nightly | Subcutaneous injection |
| Onset | Weeks to notice effect | Within hours of injection |
| Monitoring | Liver function and drug interactions | Blood pressure and injection tolerability |
Pharmacokinetic flags: flibanserin is susceptible to CYP3A4 interactions and alcohol-related hypotension risks.
Indications And Off-Label Uses In Australian Practice
Approved Indications (HSDD) And Patient Selection
Addyi and Vyleesi are approved in the United States for acquired, generalized HSDD in premenopausal women based on clinical trial data.
In Australia, prescribers must verify current TGA indications and ensure careful patient selection consistent with trial populations.
Exclude other causes of low desire such as relationship issues, depression, medication side effects or menopausal symptoms before considering pharmacotherapy.
Screening and documentation are essential for appropriate selection and risk management.
Off-Label Uses And Cautions
Off-label use can include postmenopausal libido concerns or mixed-cause sexual dysfunction, but evidence is limited.
Clinicians should document informed consent and discuss the limited evidence base and potential medico-legal implications.
Workup checklist before prescribing:
- Full medication review and reproductive health history.
- Hormone status and menopausal symptom assessment.
- Mental health and relationship factors screening.
Keep a written shared decision-making record when using medicines off-label.
Key Clinical Findings & Evidence (2022–2026)
Major trials for both drugs used validated desire scales and counts of satisfying sexual events as primary endpoints.
Flibanserin trials showed modest improvements in desire scales versus placebo in premenopausal women, balanced against side effects such as dizziness and somnolence.
Bremelanotide trials reported improvements in desire measures with common side effects of nausea and injection-site reactions.
Typical side-effect rates differ by drug but include dizziness and somnolence for flibanserin and nausea and flushing for bremelanotide.
Summary of major trials:
| Drug | Population | Design | Primary Outcome | Major AEs |
|---|---|---|---|---|
| Flibanserin | Premenopausal women with HSDD | Randomized placebo-controlled | Improved desire scores / Satisfying sexual events | Dizziness, somnolence |
| Bremelanotide | Premenopausal women with HSDD | Randomized placebo-controlled | Improved desire scores | Nausea, flushing |
Apply trial relevance cautiously to Australian patients, noting trial populations were premenopausal and excluded many comorbidities.
Alternatives Matrix — Non-Pharmacological And Pharmacological
PBS-Listed And Other Pharmaceutical Alternatives
Pharmacological alternatives depend on cause; hormonal treatments such as topical oestrogen for menopausal genitourinary symptoms have evidence for local symptoms but are not direct treatments for HSDD.
Testosterone for women is used off-label in some settings with variable evidence and regulatory status; document consent if considered.
Sildenafil is not approved for HSDD and should not be assumed effective for desire disorders.
| Treatment | Indication | Evidence Level | PBS Status | Pros / Cons |
|---|---|---|---|---|
| Flibanserin | HSDD (premenopausal) | Moderate | Likely not PBS listed | Nightly dosing, interaction risks |
| Bremelanotide | HSDD (premenopausal) | Moderate | Likely not PBS listed | On-demand injection, nausea risk |
Psychosexual And Behavioural Options
First-line care for many patients remains psychosexual therapy, CBT and couples counselling.
Stepwise care checklist:
- Detailed history and exclusion of medical causes.
- Investigations as indicated (hormones, medication review).
- Referral to psychosexual therapy or couples counselling.
- Consider pharmacotherapy only after psychosocial interventions and shared decision-making.
Costs and access vary; psychosexual services may be private or available via public sexual health clinics and mental health services.
Common Questions — Pharmacy Consultation FAQs
Below are model answers for frequent patient questions seen at the pharmacy counter.
Q: Is it safe with alcohol?
A: No for flibanserin — alcohol increases risk of hypotension and syncope; avoid alcohol while on treatment.
Q: How long until it works?
A: Flibanserin may take several weeks to show benefit; bremelanotide acts within hours of injection.
Q: Will it change my mood?
A: Mood changes are possible; screen for mental health conditions before starting.
Q: Can men use it?
A: These medicines are approved for premenopausal women with HSDD; they are not indicated for men.
Pharmacist counselling script template:
- Confirm indication and premenopausal status.
- Screen for contraindications and concurrent medicines.
- Explain dosing, side effects and alcohol warnings.
- Agree a monitoring plan and follow-up timeline.
Provide patient leaflets and signpost to GP, sexual health clinics and mental health support as needed.
Price & Access Comparison Table (Content Plan)
Pharmacy/Source, Price Range, PBS Subsidy Status
Expect private prescription costs if Addyi or Vyleesi are not PBS-listed.
Representative comparison table:
| Source | Typical Price Range (AUD) | PBS Status | Prescription Required | Risk Level |
|---|---|---|---|---|
| Community Pharmacy | Private price varies | Likely not listed | Yes | Low |
| Private Clinic | Clinic fees + private medicine cost | Likely not listed | Yes | Low–Medium |
| Unregulated Overseas Online | Variable, often cheaper | Not PBS | Varies | High |
Access Checklist For Patients (Urban Vs Rural)
- Confirm you have a valid prescription or telehealth e-script before ordering.
- Call ahead to community pharmacies for stock and counselling availability.
- Allow additional delivery time for rural areas and confirm courier cold-chain needs if any.
- Avoid unregulated overseas suppliers without a valid prescription and pharmacist support.
Registration & Regulation — TGA, PBS And Import Rules
TGA Approval Pathway And Practical Checks
Always check the TGA ARTG to confirm a medicine’s registration and approved indications before dispensing in Australia.
ARTG entries list sponsor details, approved indications and conditions of supply, which differ from PBS listing.
Note that Addyi and Vyleesi are FDA-approved for premenopausal HSDD, but Australian ARTG status must be verified for local supply.
PBS Subsidy Details & Private Prescription Implications
If a medicine is not PBS-listed, patients will pay the full private price and any associated clinic or dispensing fees.
Pharmacy staff can check PBS listings via the online PBS schedule and explain cost implications to patients.
Record-keeping steps for pharmacy staff include documenting the prescription, counselling provided and any adverse events reported to the TGA.
Storage & Handling (Household And Pharmacy)
Household Storage In Australian Climate
Store Addyi at room temperature, approximately 20–25°C, and protect it from moisture.
Store Vyleesi at room temperature within the manufacturer’s recommended range (about 15–30°C) and protect it from light and excessive heat.
Avoid storing medicines in bathrooms or cars where Australian summer temperatures and humidity can be high.
Keep all medicines out of reach of children.
Pharmacy And Cold-Chain Handling
Vyleesi autoinjectors require pharmacy handling to include expiry checks and storage away from direct light and heat.
Pharmacies dispensing injectable devices should provide injection training and written sharps disposal instructions.
| Product | Storage Temp | Shelf Life / Transport Tips |
|---|---|---|
| Flibanserin (Addyi) | 20–25°C | Protect from moisture; avoid high heat |
| Bremelanotide (Vyleesi) | 15–30°C | Protect from light and heat; provide injection counselling |
Guidelines For Proper Use And Pharmacist Counselling Style
Structured Counselling Script For Australian Pharmacists
Start by confirming the indication and the patient’s premenopausal status if relevant.
Use the contraindication checklist to screen for pregnancy, breastfeeding, severe hepatic impairment, alcohol use and interacting medicines.
Explain the regimen clearly: nightly for flibanserin; pre-sex injection for bremelanotide.
Discuss common side effects and provide clear alcohol warnings for flibanserin.
Agree a monitoring plan including a review at 4–8 weeks for flibanserin and follow-up after several uses of bremelanotide.
Document consent and counselling in the patient record.
Patient Follow-Up And Reporting
Recommend a follow-up review at around eight weeks for Addyi to assess benefit and tolerability.
For Vyleesi, arrange a review after multiple uses to assess efficacy and side effects such as nausea or blood pressure effects.
Report suspected adverse reactions to the TGA through their Adverse Event reporting portal.
Provide referral pathways to sexual health clinics, GPs and mental health services as indicated.
Offer downloadable counselling aids such as a quick reference card and an adverse-event diary for patients.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 14-21 days |
| Wollongong | New South Wales | 14-21 days |
| Geelong | Victoria | 14-21 days |
| Townsville | Queensland | 14-21 days |
| Cairns | Queensland | 14-21 days |
| Darwin | Northern Territory | 14-21 days |